艾塞那肽及西格列汀联合二甲双胍治疗2型糖尿病的疗效比较

Comparison of the Efficacy of Exenatide and Sitagliptin Combined with Metformin in the Treatment of Type 2 Diabetes

目的比较二甲双胍分别联合艾塞那肽与西格列汀治疗2型糖尿病(T2DM)的疗效及对血清HbA1c水平的影响。方法将该院2018年1月-2019年3月收治的108例2型糖尿病患者为研究对象,并随机分为艾塞那肽组和西格列汀组,两组各54例。其中艾塞那肽组给予艾塞那肽联合二甲双胍,西格列汀组给予西格列汀联合二甲双胍治疗,疗程均为2个月。观察两组治疗前后的糖化血红蛋白、空腹血糖(FBG)、体重指数、餐后2 h血糖等指标的变化,评价药物疗效。结果治疗后两组患者HbA1c、FBG、2 hPG、体重指数较治疗前均下降(P<0.05),且艾塞那肽组的HbA1c、FBG、2 hPG及体质量下降幅度明显高于西格列汀组(P<0.05)。结论二甲双胍分别与艾塞那肽和西格列汀联合应用于2型糖尿病的治疗均能有效控制T2DM患者血糖、体重和降低HbA1c水平,安全性均较高,但艾塞那肽的疗效更显著。

Objective To compare the efficacy of metformin combined with exenatide and sitagliptin in the treatment of type 2 diabetes(T2DM)and the effect on serum HbA1c level.Methods 108 patients with type 2 diabetes admitted in the hospital from January 2018 to March 2019 were selected as study subjects,and randomly divided into exenatide group and sitagliptin group,54 cases in each group.The exenatide group was given exenatide combined with metformin,and the sitagliptin group was given sitagliptin combined with metformin for two months.Observe the changes of glycated hemoglobin,fasting blood glucose(FBG),body mass index,2 h postprandial blood glucose and other indexes before and after treatment in both groups to evaluate the efficacy of drugs.Results After treatment,the HbA1c,FBG,2 hPG and body mass index of the two groups of patients decreased compared with before treatment(P<0.05),and the extinction group HbA1c,FBG,2 hPG and body mass decreased significantly more than the sitagliptin group(P<0.05).Conclusion Metformin combined with exenatide and sitagliptin in the treatment of type 2 diabetes can effectively control blood glucose,body weight and reduce HbA1c levels in T2DM patients,and the safety is higher,but the efficacy of exenat peptides is more significant.